JP2020510628A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510628A5
JP2020510628A5 JP2019532019A JP2019532019A JP2020510628A5 JP 2020510628 A5 JP2020510628 A5 JP 2020510628A5 JP 2019532019 A JP2019532019 A JP 2019532019A JP 2019532019 A JP2019532019 A JP 2019532019A JP 2020510628 A5 JP2020510628 A5 JP 2020510628A5
Authority
JP
Japan
Prior art keywords
plasminogen
use according
pharmaceutical composition
drug
islet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019532019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510628A (ja
JP7554557B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2017/089069 external-priority patent/WO2018107708A1/zh
Publication of JP2020510628A publication Critical patent/JP2020510628A/ja
Publication of JP2020510628A5 publication Critical patent/JP2020510628A5/ja
Priority to JP2022119582A priority Critical patent/JP2022166028A/ja
Application granted granted Critical
Publication of JP7554557B2 publication Critical patent/JP7554557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019532019A 2016-12-15 2017-06-19 インスリン受容体基質－２の発現を促進する方法 Active JP7554557B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022119582A JP2022166028A (ja) 2016-12-15 2022-07-27 インスリン受容体基質－２の発現を促進する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/110171 2016-12-15
CNPCT/CN2016/110171 2016-12-15
PCT/CN2017/089069 WO2018107708A1 (zh) 2016-12-15 2017-06-19 一种促进胰岛素受体底物-2表达的方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022119582A Division JP2022166028A (ja) 2016-12-15 2022-07-27 インスリン受容体基質－２の発現を促進する方法

Publications (3)

Publication Number Publication Date
JP2020510628A JP2020510628A (ja) 2020-04-09
JP2020510628A5 true JP2020510628A5 (enExample) 2020-07-30
JP7554557B2 JP7554557B2 (ja) 2024-09-20

Family

ID=62557852

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2019532017A Active JP7175270B2 (ja) 2016-12-15 2017-06-19 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2019531895A Active JP7171572B2 (ja) 2016-12-15 2017-06-19 糖尿病を治療するための新しい方法
JP2019532019A Active JP7554557B2 (ja) 2016-12-15 2017-06-19 インスリン受容体基質－２の発現を促進する方法
JP2019532043A Active JP7554048B2 (ja) 2016-12-15 2017-06-19 インスリン分泌を促進する方法
JP2022119543A Pending JP2022166026A (ja) 2016-12-15 2022-07-27 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2022119582A Pending JP2022166028A (ja) 2016-12-15 2022-07-27 インスリン受容体基質－２の発現を促進する方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2019532017A Active JP7175270B2 (ja) 2016-12-15 2017-06-19 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2019531895A Active JP7171572B2 (ja) 2016-12-15 2017-06-19 糖尿病を治療するための新しい方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019532043A Active JP7554048B2 (ja) 2016-12-15 2017-06-19 インスリン分泌を促進する方法
JP2022119543A Pending JP2022166026A (ja) 2016-12-15 2022-07-27 グルカゴン、インスリンを正常なバランスに戻らせる方法
JP2022119582A Pending JP2022166028A (ja) 2016-12-15 2022-07-27 インスリン受容体基質－２の発現を促進する方法

Country Status (9)

Country Link
US (4) US11129880B2 (enExample)
EP (4) EP3556392B1 (enExample)
JP (6) JP7175270B2 (enExample)
CN (4) CN110139667A (enExample)
CA (4) CA3047176C (enExample)
DK (1) DK3556383T5 (enExample)
ES (1) ES2981141T3 (enExample)
TW (7) TW201822803A (enExample)
WO (7) WO2018107701A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
CA3067890A1 (en) * 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
CN111411072B (zh) * 2020-03-09 2022-10-11 同济大学 SLC30A8基因表达下调的抗糖尿病胰岛β细胞及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
GB8721951D0 (en) 1987-09-18 1987-10-28 Thrombosis Research Trust Organic compounds
JP2764264B2 (ja) 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
WO1994001128A1 (en) 1992-07-01 1994-01-20 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
DK125693D0 (enExample) 1993-11-05 1993-11-05 Novo Nordisk As
DE4411143C2 (de) 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
MX9708217A (es) 1995-04-26 1997-12-31 Childrens Medical Center Fragmentos de angiostatina y angiostatina agregada y metodos de uso.
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US5955627A (en) 1996-12-16 1999-09-21 Kuraray Co., Ltd. Process for the preparation of cyclopropylacetylene derivatives
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
JP3561154B2 (ja) 1997-12-26 2004-09-02 株式会社東芝 放送受信装置および契約管理装置
US6728260B2 (en) 1998-06-26 2004-04-27 Intel Corporation Switch and/or router unit
ES2276536T3 (es) 1998-09-29 2007-06-16 LEUVEN RESEARCH & DEVELOPMENT VZW Uso de compuestos que reducen las alfas2-antiplasminas in vivo para la preparacion de una composicion para el tratamiento del ictus isquemico.
EP1147202A2 (en) 1999-01-28 2001-10-24 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
US6733750B1 (en) 1999-03-09 2004-05-11 Minu, L.L.C. Process and composition for inducing posterior vitreous detachment
US20030014787P1 (en) 1999-03-31 2003-01-16 Olesen L. Pernille Floribunda rose variety 'POULfeld'
CA2385703A1 (en) 1999-10-07 2001-04-12 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
US6964764B2 (en) 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US20020159992A1 (en) 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US6596785B2 (en) 2001-07-17 2003-07-22 Foamex L.P. Ink retaining foam structure
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
MXPA04007585A (es) 2002-02-06 2005-09-20 N Zyme Biotec Gmbh Metodo para la produccion de proteinas recombinantes en microorganismos.
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US7075933B2 (en) 2003-08-01 2006-07-11 Nortel Networks, Ltd. Method and apparatus for implementing hub-and-spoke topology virtual private networks
JP4740531B2 (ja) 2003-09-30 2011-08-03 雪印乳業株式会社 骨吸収抑制剤
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
WO2006023864A1 (en) 2004-08-23 2006-03-02 Wyeth Pyrrolo-naphthyl acids as pai-1 inhibitors
MX2007002178A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de oxazolo-naftilo como moduladores del inhibidor del activador de plasminogeno tipo 1 (pai-1) util en el tratamiento de trombosis y enfermedades cardiovasculares.
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
US8064439B2 (en) 2005-06-30 2011-11-22 Cisco Technology, Inc. Method and system for call processing
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
CA2662101C (en) * 2006-08-28 2015-07-07 Omnio Healer Ab Candidates against infection
US20100080773A1 (en) 2008-09-26 2010-04-01 Sdg, Inc. Orally Bioavailable Lipid-Based Constructs
WO2009054439A1 (ja) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
US8101394B2 (en) * 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin
US20090208448A1 (en) * 2008-02-15 2009-08-20 Solomon Keith R Inhibition of angiogenesis
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
EP2424561A2 (en) * 2009-04-30 2012-03-07 Catherine Blondel Methods for treating ocular conditions
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
CA2844644A1 (en) * 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
DK2914575T3 (da) 2012-10-31 2021-01-18 Univ Michigan Regents Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
BR112016002753A2 (pt) 2013-08-13 2017-11-21 Sanofi Sa anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
WO2015057968A2 (en) * 2013-10-17 2015-04-23 The General Hospital Corporation Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same
CN104789544B (zh) * 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
PY1577621A (es) 2014-12-19 2017-10-02 Prometic Biotherapeutics Inc Composicion farmaceutica que comprende plasminogeno y uso para el mismo
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
WO2017101866A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种用于预防或治疗急性及慢性血栓的方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
TWI750189B (zh) 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
US11642397B2 (en) 2017-12-15 2023-05-09 Talengen International Limited Method and drug for preventing or treating osteoarthritis

Similar Documents

Publication Publication Date Title
Li et al. Physically cross-linked DNA hydrogel-based sustained cytokine delivery for in situ diabetic alveolar bone rebuilding
Wang et al. Progress in mesenchymal stem cell–based therapy for acute liver failure
Giorgino et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)
JP2009503093A5 (enExample)
Liu et al. Improvement of transdermal delivery of exendin-4 using novel tip-loaded microneedle arrays fabricated from hyaluronic acid
Van Gaal et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program
Rosenstock et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial
ES2653615T3 (es) Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos
JP2020502151A5 (enExample)
Rave et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro
Rosenstock et al. Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents
JP2018138578A5 (enExample)
Ji et al. Niche-dependent regulations of metabolic balance in high-fat diet–induced diabetic mice by mesenchymal stromal cells
EP2976096B1 (en) Insulin dosing regimen
Scheen GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?
CN110366426A (zh) 一种促进胰岛素分泌的方法
CN101027082A (zh) 降低2型糖尿病患者血清胰岛素原水平的方法
JP2020502150A5 (enExample)
Wu et al. Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial
JP2020502140A5 (enExample)
JP2012509283A5 (enExample)
Chen et al. Therapeutic effects of self-assembled tetrahedral framework nucleic acids on liver regeneration in acute liver failure
Bistola et al. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
IL272893B2 (en) Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
Mittermayer et al. Addressing unmet medical needs in type 1 diabetes: a review of drugs under development